Brief: Santen Announces U.S. FDA Filing Acceptance Of New Drug Application (NDA) For Cyclosporine Topical Ophthalmic Emulsion, 0.1%

SANTEN PHARMACEUTICAL

26/10/2020 11:47

Oct 26 (Reuters) - Santen Pharmaceutical Co Ltd  4536.T :
    * SANTEN ANNOUNCES U.S. FDA FILING ACCEPTANCE OF NEW DRUG
APPLICATION (NDA) FOR CYCLOSPORINE TOPICAL OPHTHALMIC EMULSION,
0.1% FOR THE TREATMENT OF SEVERE VERNAL KERATOCONJUNCTIVITIS IN
PATIENTS AGES 4-18
    * SANTEN INC - FDA HAS SET JUNE 26, 2021 AS PDUFA GOAL DATE
FOR
CYCLOSPORINE TOPICAL OPHTHALMIC EMULSION

Source text for Eikon:  ID:nCNWzMGJNa 
Further company coverage:  4536.T 

 ((Reuters.Briefs@thomsonreuters.com;))